Funding Information
Ministry of Health Malaysia, Grant/Award Number: NMRR-16-884-31002/JPP-IMR [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] To the Editor, Hypersensitivity drug reactions (HDRs) are an immense public health problem where significant proportions may lead to mortality.
HDRs can manifest in various phenotypes, mainly cutaneous reactions that range from the mild, that is exanthem, urticaria and angioedema to the critical, that is severe cutaneous adverse reactions (SCARs).
SCARs are life-threatening reactions that include Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS) or drug-induced hypersensitivity syndrome (DIHS) and less commonly, acute generalized exanthematous pustulosis (AGEP). Previously, these reactions were unavoidable as they are linked to the intrinsic properties of drugs and an individual's genetic predisposition. Nevertheless, with the advent of pharmacogenomics and the vast pharmacogenetic studies performed in the last two decades, this is set to change in future.
Today, pharmacogenomics is viewed as a highly substantial field for improving drug therapy and prescription of personalized medicine. Furthermore, technological advancement in pharmacogenomics research has greatly improved our understanding of adverse drug reactions. Pharmacogenomics research not only tailors therapeutics to an individual's make-up (disease phenotype, genetic, environmental and clinical manifestations) but also maximizes success of drug therapy and minimizes any potential adverse effects. (Table S1 ). Screening for these specific HLA-B alleles has been recommended before treatment initiation. However, there are no clear guidelines on the alert mechanism when the HDR-related HLA alleles were found incidentally, during an HLA-related genetic research. In this study, we aimed to formulate a suitable alert system to assist primary prevention of potential HDRs when incidental findings of HLA-B associated alleles for carbamazepine, phenytoin, allopurinol and/or abacavir were observed in an HLA-related genetic research. A total of 68 subjects were recruited in a case-control study investigating the HLA associations with non-steroidal anti-inflamma- In this study, we found that the HLA-B alleles did not deviate from the Hardy-Weinberg equilibrium for all studied subjects Table S3 . The PPV ranges from 2.7% and 76.7%, and NPV is observed to be more than 97% for the related drug in the studied population. Taken together, the low to moderate PPV and high NPV with severity of HDR shows that benefits of HLA screening outweigh the risks, supporting the recommendation by the Clinical Pharmacogenetics Implementation Consortium (CPIC). Thus, disclosure of incidental HLA findings in our study serves as a clinical utility to the study participants. 5 It is noteworthy that potential benefits and risks are associated with HLA screening to patients. A benefit of genetic testing is the avoidance of adverse effects in carriers of HDR-associated HLA-B* alleles, reducing the incidence of life-threatening reactions. In addition, these at-risk individuals may be prescribed alternative drugs that are relatively effective and safer.
However, the risk of genotyping error during HLA-screening could have significant healthcare impacts. These include misleading risk variants identification and unnecessary contraindication of the respective drug in patients who do not develop HDR.
As the current practice of the allergy card in Malaysia is strictly for secondary prevention, we opted for the medic alert bracelet as a 
ACKNOWLEDGEMENTS
We would like to thank the Director General of Health Malaysia for his permission to publish this article. We also thank all the subjects who volunteered to participate in this project and all the clinical and laboratory staff that were involved in this pilot project.
This study was financially supported by Ministry of Health Malaysia: NMRR-16-884-31002/JPP-IMR 16-028.
CONF LICT OF I NTEREST
All the authors declare no conflict of interest.
O R C I D

Mohammed Faizal Bakhtiar
https://orcid.org/0000-0002-0203-9510
